ALVAL.PA
Valbiotis SA [ALVAL.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALVAL.PA Stock Summary
In the News
ALVAL.PA Financial details
Company Rating
-
Market Cap
62.32M
Income
-19.45M
Revenue
5.18M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
48
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-4.03
Forward P/E
-
PEG
-0.4
P/S
28.93
P/B
3.72
P/C
-
P/FCF
-8.17
Quick Ratio
2.57
Current Ratio
3
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.91
EPS next Y
-
EPS next Q
-
EPS this Y
28.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.56%
Revenue last 5Y
58.29%
Revenue Q/Q
2727.33%
EPS Q/Q
-76.81%
-
-
-
-
SMA20
-4.88%
SMA50
-6.02%
SMA100
-32.76%
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
-89%
ROC
-0.63%
Gross Margin
79%
Oper. Margin
-449%
Profit Margin
-460%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.82-7.5
52W High
-89.06%
52W Low
-61.7%
RSI
43.87
Rel Volume
3.76
Avg Volume
33.43K
Volume
125.7K
Perf Week
-5.43%
Perf Month
-5.55%
Perf Quarter
-23.4%
Perf Half Y
-21.85%
-
-
-
-
Beta
-0.299
-
-
Volatility
0.02%, 0.03%
Prev Close
3.37%
Price
0.766
Change
-2.42%
Company Profile
- Volume Average 33.43K
- Market Capitalization 62.32M
- Employee 48
- CEO Mr. Sebastien Peltier HDR, Ph.D.
- Headquarters Périgny,FR
- IPO Date 2017-06-07
-
Website
https://www.valbiotis.com 
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
